JP2007509932A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509932A5
JP2007509932A5 JP2006537956A JP2006537956A JP2007509932A5 JP 2007509932 A5 JP2007509932 A5 JP 2007509932A5 JP 2006537956 A JP2006537956 A JP 2006537956A JP 2006537956 A JP2006537956 A JP 2006537956A JP 2007509932 A5 JP2007509932 A5 JP 2007509932A5
Authority
JP
Japan
Prior art keywords
carbon atoms
pharmaceutical composition
alkyl
phenyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006537956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509932A (ja
Filing date
Publication date
Priority claimed from US10/699,110 external-priority patent/US7776907B2/en
Application filed filed Critical
Publication of JP2007509932A publication Critical patent/JP2007509932A/ja
Publication of JP2007509932A5 publication Critical patent/JP2007509932A5/ja
Abandoned legal-status Critical Current

Links

JP2006537956A 2003-10-30 2004-04-28 黄斑変性症の治療用サイトカイン阻害薬 Abandoned JP2007509932A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/699,110 US7776907B2 (en) 2002-10-31 2003-10-30 Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
PCT/US2004/013253 WO2005044269A1 (en) 2003-10-30 2004-04-28 Cytokine inhibitory drugs for treatment of macular degeneration

Publications (2)

Publication Number Publication Date
JP2007509932A JP2007509932A (ja) 2007-04-19
JP2007509932A5 true JP2007509932A5 (OSRAM) 2007-06-07

Family

ID=34573277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006537956A Abandoned JP2007509932A (ja) 2003-10-30 2004-04-28 黄斑変性症の治療用サイトカイン阻害薬

Country Status (11)

Country Link
US (3) US7776907B2 (OSRAM)
EP (1) EP1684756A4 (OSRAM)
JP (1) JP2007509932A (OSRAM)
KR (1) KR20060108695A (OSRAM)
CN (1) CN1901909A (OSRAM)
AU (1) AU2004286824A1 (OSRAM)
BR (1) BRPI0415970A (OSRAM)
CA (1) CA2543618A1 (OSRAM)
IL (1) IL175311A0 (OSRAM)
WO (1) WO2005044269A1 (OSRAM)
ZA (1) ZA200603463B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
RU2536865C2 (ru) 2009-05-14 2014-12-27 Тяньцзинь Химэй Байо-Тек Ко., Лтд. Производные тиофена
CN103402980B (zh) * 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
WO2022125925A1 (en) * 2020-12-11 2022-06-16 Cognition Therapeutics, Inc. Compositions for treating dry age-related macular degeneration (amd)

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FR2649072B1 (fr) * 1989-06-30 1991-11-29 Design Agc Sarl Conteneur en materiau thermoplastique moule en une seule piece et equipe d'une trompe verseuse
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5633947A (en) * 1991-03-21 1997-05-27 Thorn Emi Plc Method and apparatus for fingerprint characterization and recognition using auto correlation pattern
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5675533A (en) * 1994-09-26 1997-10-07 Texas Instruments Incorporated Semiconductor device
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US5689579A (en) * 1996-01-17 1997-11-18 J.D. Carreker And Associates, Inc. Rule-based circuit, method and system for performing item level reconciliation
NO310106B1 (no) * 1996-03-13 2001-05-21 Norsk Hydro As Mikroporöse, krystallinske metallofosfatforbindelser, en fremgangsmåte for fremstilling og anvendelse derav
JP4214537B2 (ja) * 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
JP2001511448A (ja) 1997-07-31 2001-08-14 セルジーン コーポレイション 置換アルカノヒドロキサム酸およびＴＮＦαレベルの減少方法
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
AU749356B2 (en) 1998-05-11 2002-06-27 Children's Medical Center Corporation Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
DE19831217A1 (de) 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2000159761A (ja) 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6727364B2 (en) * 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
AU2003222034A1 (en) 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP1567148A4 (en) * 2002-10-31 2010-09-15 Celgene Corp METHOD OF USE AND COMPOSITIONS WITH SELECTIVE CYTOKINE INHIBITORS FOR THE TREATMENT AND SUPPLEMENT OF MACULAR DEGENERATION
KR20090048520A (ko) * 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
JP5269281B2 (ja) * 2002-12-30 2013-08-21 セルジーン コーポレイション フルオロアルコキシ置換１，３−ジヒドロイソインドリル化合物およびそれらの医薬としての使用
BRPI0408005A (pt) * 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
ES2362484T3 (es) * 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
CN1784382A (zh) * 2003-03-12 2006-06-07 细胞基因公司 7－氨基－异吲哚基化合物及其药物用途

Similar Documents

Publication Publication Date Title
RU2419624C2 (ru) Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2
JP2023541522A5 (OSRAM)
JP2007519649A5 (OSRAM)
MX2011005667A (es) Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor.
JP2005526064A5 (OSRAM)
US11660281B2 (en) Compositions and methods of treating or preventing fibrotic lung diseases
JP5053503B2 (ja) 過増殖状態を処置するための方法および組成物
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
JP2023530316A5 (OSRAM)
JP2012517441A5 (OSRAM)
JP2022521380A5 (OSRAM)
WO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
MX2007006992A (es) Composiciones que comprenden moduladores pde4 y su uso para el tratamiento o prevencion de la inflamacion de las vias aereas.
JP2005508363A5 (OSRAM)
JP6687550B2 (ja) 肝疾患又は肝機能異常を治療するためのアプレミラスト
JP2006507307A (ja) 黄斑変性を治療、予防および管理するための方法
US20110038832A1 (en) Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US20030176488A1 (en) Method for treating depression
AU2014284304B2 (en) Method of treating neurodegenerative disorders
AU2003285107B2 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
JP2006508118A5 (OSRAM)
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
RU2007115092A (ru) Аминоспиртовые производные
CN117396505A (zh) 治疗炎症的方法
EP1623741A2 (en) Cannabinoid receptor ligands for hair growth modulation